top of page

Home  ›  Health News Today  ›  Health News Today, Nov 18: Recalls, Heart Drugs, Medicare

✓ Fact-Checked & NIH-Cited  •  Updated November 18, 2026

Health News Today, Nov 18: Recalls, Heart Drugs, Medicare

Writer: Mr Steady Natural Health
Mr Steady Natural Health
14 hours ago
5 min read

Welcome to today's health briefing for November 18, 2026, delivering essential updates for staying proactive about your well-being. Today’s highlights feature an urgent federal food safety recall, groundbreaking cardiovascular clinical trials, and critical Medicare coverage reminders. Here is what you need to know about the latest developments and how they impact you.

FDA and CDC Issue Recall on Organic Carrots Over E. Coli Risk

The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have issued an urgent warning and nationwide voluntary recall regarding multiple brands of organic whole and baby carrots distributed by Grimmway Farms. Health authorities linked the produce to a multistate outbreak of Shiga toxin-producing Escherichia coli O121:H19. The outbreak has resulted in dozens of illnesses across 18 states, leading to multiple hospitalizations and one confirmed death. Impacted store brands include widely purchased labels such as 365, Bunny Luv, Cal-Organic, Nature's Promise, and Trader Joe's. While retailers have pulled affected bags from grocery shelves, federal officials caution that many consumers still store these long-lasting carrots in household refrigerators or home freezers. Shiga toxin-producing infections pose serious health dangers, including severe stomach cramps, bloody diarrhea, and potentially life-threatening kidney complications known as Hemolytic Uremic Syndrome (HUS). Official investigation details and full brand listings are available through the FDA Recall Alert and the CDC Outbreak Notice.

What it means for you: Check your refrigerator and freezer immediately for recalled bagged organic carrots, throw them away if identified, and thoroughly sanitize any produce bins or surfaces they touched. If you or a family member over 45 develop severe abdominal pain or persistent gastrointestinal symptoms, contact a healthcare provider promptly for guidance.

Tirzepatide Cuts Heart Failure Risk by 38% in Landmark Trial

Groundbreaking clinical findings presented at the American Heart Association (AHA) Scientific Sessions and published in The New England Journal of Medicine (NEJM SUMMIT Study) show that tirzepatide delivers dramatic therapeutic benefits for patients with heart failure with preserved ejection fraction (HFpEF) and obesity. In the landmark phase 3 SUMMIT trial involving 731 participants, treatment with tirzepatide led to a remarkable 38% reduction in the combined risk of cardiovascular death or worsening heart failure events requiring urgent hospitalization or intravenous therapy compared to placebo. Participants receiving the medication also demonstrated substantial gains in physical functional capacity, walking endurance, and overall health-related quality of life, alongside marked reductions in systemic inflammation markers. HFpEF has historically presented a steep clinical challenge because conventional heart medications frequently fail to alter long-term disease outcomes in this specific population.

What it means for you: Because HFpEF accounts for nearly half of all heart failure cases and primarily affects older adults, these findings represent an encouraging advance in cardiovascular management. If you navigate heart failure alongside metabolic or weight challenges, discuss these newly published clinical findings with your cardiologist to explore suitable management options.

New Oral Drug Muvalaplin Slashes Dangerous Lp(a) Cholesterol

In late-breaking clinical results published in The Journal of the American Medical Association (JAMA KRAKEN Study), researchers revealed that an investigational oral pill named muvalaplin significantly lowers Lipoprotein(a), commonly known as Lp(a). Elevated Lp(a) is a highly atherogenic, genetically determined cardiovascular risk factor affecting roughly one in five adults worldwide, significantly accelerating plaque buildup, coronary artery disease, and stroke. Unlike traditional low-density lipoprotein (LDL) cholesterol, Lp(a) levels cannot be substantially modified through diet, exercise, or widely prescribed statin medications. In the phase 2 KRAKEN trial involving 233 adults with elevated cardiovascular risk, daily oral muvalaplin achieved dose-dependent reductions in circulating Lp(a) concentrations of up to 70% to 86%, while demonstrating an overall adverse event profile comparable to placebo.

What it means for you: While muvalaplin remains in clinical evaluation and is not yet available at retail pharmacies, these results offer meaningful encouragement for individuals with strong family histories of early cardiac disease. Ask your physician during your next routine checkup whether evaluating your Lp(a) level is appropriate for your overall cardiovascular risk assessment.

Strict Blood Pressure Goal Below 120 Lowers Diabetes Heart Risks

A major clinical trial presented at the AHA Scientific Sessions and published in The New England Journal of Medicine (NEJM BPROAD Study) demonstrates that intensive blood pressure control provides substantial cardiac protection for individuals managing type 2 diabetes. The multicenter BPROAD trial enrolled over 12,800 participants with type 2 diabetes and hypertension, comparing an intensive systolic blood pressure target of under 120 mm Hg against the standard clinical goal of under 140 mm Hg over four years of follow-up. Patients in the intensive treatment group experienced a significant 21% reduction in major adverse cardiovascular events, including nonfatal heart attack, nonfatal stroke, and cardiovascular death. However, researchers noted that patients aiming for the lower target experienced higher rates of lightheadedness, symptomatic low blood pressure, and electrolyte changes.

What it means for you: If you live with both hypertension and type 2 diabetes, this study underscores the protective power of tight vascular control, but targets must remain personalized. Talk with your primary care provider before making any changes to your medication routine to determine the safest blood pressure range for your individual health status.

Medicare Advantage Disruptions Prompt Urgent Enrollment Review

As the annual Medicare Open Enrollment window progresses toward its December 7 closing deadline, federal updates from the Centers for Medicare & Medicaid Services (CMS Prescription Payment Plan Details) and investigative reporting from CNN Health urge older adults to review their policies carefully. Many private Medicare Advantage insurers are scaling back regional coverage areas, altering provider networks, or trimming supplemental benefits like dental, vision, and hearing allowances for the upcoming 2025 calendar year. At the same time, major Medicare Part D reforms will implement a hard $2,000 cap on annual out-of-pocket prescription medication costs. Health policy analysts caution, however, that this spending cap only protects drugs included on a plan's specific formulary, meaning an overlooked plan change could result in higher out-of-pocket costs or dropped provider access.

What it means for you: Do not allow your coverage to automatically renew without inspecting your plan's Annual Notice of Change (ANOC) letter. Visit Medicare.gov or speak with a licensed State Health Insurance Assistance Program (SHIP) counselor to verify that your current prescriptions and preferred physicians remain covered for 2025 before the December 7 deadline.

Related reading: health news updates Nov 19.

Sources

This roundup is for general information only and is not medical advice.

Related Posts

See All

EDITORIAL & RESEARCH STANDARDS

Steady Natural Health Research & Fact-Checking Team

Every guide and supplement audit is cross-checked against U.S. government nutrition databases (NIH Office of Dietary Supplements, PubMed human trials, and FDA notices) for adults 45+. Our writers are health science researchers, not personal physicians—always discuss supplements with your doctor or pharmacist.

Editorial Policy  •  Affiliate Disclosure  •  Medical Disclaimer

bottom of page